Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report

[1]  B. Morland,et al.  Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group , 2018, Pediatric blood & cancer.

[2]  Yukichi Tanaka,et al.  Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. , 2017, The Lancet. Oncology.

[3]  K. Pritchard-Jones,et al.  Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens , 2016, Cancer Chemotherapy and Pharmacology.

[4]  D. Murphy,et al.  Carboplatin therapeutic monitoring in preterm and full-term neonates , 2015, European journal of cancer.

[5]  Nicolas Widmer,et al.  Therapeutic drug monitoring in cancer--are we missing a trick? , 2014, European journal of cancer.

[6]  B. Morland,et al.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study , 2013, The Lancet. Oncology.

[7]  V. Vallon,et al.  Functional Maturation of Drug Transporters in the Developing, Neonatal, and Postnatal Kidney , 2011, Molecular Pharmacology.

[8]  E. Wiemer,et al.  Drug transporters of platinum-based anticancer agents and their clinical significance. , 2011, Drug resistance updates.

[9]  B. Morland,et al.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. , 2009, The New England journal of medicine.

[10]  Xingguo Cheng,et al.  Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. , 2008, Life sciences.

[11]  J. Stocker.  Hepatic tumors in children. , 2001, Clinics in liver disease.

[12]  A. Guarino,et al.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. , 1977, Biochemical medicine.